Professor Thomas Powles MBBS, MD, MRCP

Professor Powles is the Academic Leader for Urology Cancer. He is also the Lead for solid tumours at the CRUK Experimental Cancer Medicine Centre. He qualified with an MB BS at Barts in 1995 and has been based here Barts Health NHS Trust since 2007, where he is currently the Clinical Lead of the multi-disciplinary group. His research focuses on the mechanisms of resistance to therapy in urology cancer. He leads clinical trials in all stages and is involved in drug development as well as investigating biomarkers to predict response to therapy. His focus in testis cancer is on redefining the treatment of patients with relapsed disease. Professor Powles is leading an international collaboration testing conventional dose therapy and high dose therapy.

A selection of recent publications

Active surveillance is the preferred approach to clinical stage I testicular cancer.

J Clin Oncol. 2013 Oct 1;31(28):3490-3. doi: 10.1200/JCO.2012.47.6010. Epub 2013 Sep 3. No abstract available. 

Nichols CR, Roth B, Albers P, Einhorn LH, Foster R, Daneshmand S, Jewett M, Warde P, Sweeney CJ, Beard C, Powles T, Tyldesley S, So A, Porter C, Olgac S, Fizazi K, Hayes-Lattin B, Grimison P, Toner G, Cathomas R, Bokemeyer C, Kollmannsberger C.

Bone metastases in germ cell tumours: lessons learnt from a large retrospective study. BJU Int. 2013 Jul;112(2):176-81. doi: 10.1111/bju.12218

Jamal-Hanjani M, Karpathakis A, Kwan A, Mazhar D, Ansell W, Shamash J, Harper P, Rudman S, Powles T, Chowdhury S.

Prognostic impact of LDH levels in patients with relapsed/refractory seminoma.

J Cancer Res Clin Oncol. 2013 Aug;139(8):1311-6. doi: 10.1007/s00432-013-1442-0. Epub 2013 May Powles T, Bascoul-Mollevi C, Kramar A, Lorch A, Beyer J.

Was this page useful?